Related Experiment Videos
Hypothalamic-pituitary-adrenal axis and bipolar disorder
1Bipolar Disorders Program, Hospital Clinic, University of Barcelona, Barcelona, Spain.
The Psychiatric Clinics of North America
|April 14, 2005
Summary
Abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis, including hypercortisolism, are linked to bipolar disorder symptoms. Targeting the HPA axis, potentially via glucocorticoid receptor (GR) antagonism, shows promise for future mood disorder treatments.
Area of Science:
- Neuroscience
- Psychiatry
- Endocrinology
Background:
- Bipolar disorder is characterized by mood disturbances and cognitive deficits.
- The hypothalamic-pituitary-adrenal (HPA) axis shows significant abnormalities in individuals with bipolar disorder.
- Hypercortisolism is implicated in the pathophysiology of depressive symptoms and cognitive impairment in bipolar disorder.
Purpose of the Study:
- To review the role of HPA axis dysregulation in bipolar disorder.
- To explore the potential of HPA axis modulation as a therapeutic strategy for mood disorders.
- To investigate glucocorticoid receptor (GR) antagonism as a future treatment approach.
Main Methods:
- Review of existing preclinical and clinical studies on HPA axis function in bipolar disorder.
- Analysis of the relationship between cortisol levels, mood symptoms, and cognitive deficits.
- Evaluation of therapeutic interventions targeting the HPA axis.
Main Results:
- Robust evidence links HPA axis abnormalities to bipolar disorder.
- Elevated cortisol levels may contribute to depressive symptoms and neurotoxicity.
- Increased ACTH and cortisol precede manic episodes, causing cognitive and functional impairments.
Conclusions:
- HPA axis dysregulation is central to bipolar disorder pathogenesis.
- Current treatments may not fully address mood and cognitive symptoms.
- Targeting the HPA axis, particularly GR antagonism, represents a promising therapeutic avenue for mood disorders.